Tobramycin

Aminoglycoside Antibacterial — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Tobramycin is an ofp drug in the Aminoglycoside Antibacterial class catalogued in DrugCentral. It was first approved by the FDA in 1975. DrugCentral lists 3 molecular targets, including HPSE, mphB and TAS2R20. Recorded indications include Allergic conjunctivitis, Anterior uveitis, Bacterial conjunctivitis and Bacterial infection due to Klebsiella pneumoniae.

• Approval status: ofp (first approved 1975 by the FDA).
• Drug class: Aminoglycoside Antibacterial.
• Molecular targets: HPSE, mphB and TAS2R20 (3 listed in DrugCentral).
• Indications: Allergic conjunctivitis, Anterior uveitis, Bacterial conjunctivitis, Bacterial infection due to Klebsiella pneumoniae and Bacterial infection due to Serratia and others.
• ATC code: J01GB01 (Other aminoglycosides).
• Molecular formula: C18H37N5O9; molecular weight 467.52 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (59)

• Allergic conjunctivitis
• Anterior uveitis
• Bacterial conjunctivitis
• Bacterial infection due to Klebsiella pneumoniae
• Bacterial infection due to Serratia
• Bacterial meningitis
• Bacterial peritonitis
• Bacterial septicemia
• Bacterial urinary infection
• Blepharoconjunctivitis
• Citrobacter Complicated UTI
• Complicated Proteus UTI
• Complicated Urinary Tract Infections
• Complicated UTI with Pseudomonas Aeruginosa
• Corneal abrasion
• Dacryocystitis
• E. Coli Osteomyelitis
• E. Coli Peritonitis
• Enterobacter Osteomyelitis
• Enterobacter Pneumonia
• Escherichia coli urinary tract infection
• Gram-Negative Aerobic Bacillary Pneumonia
• Herpes zoster keratitis
• Infection due to Enterobacteriaceae
• Infection due to Escherichia coli
• Infection due to Staphylococcus aureus
• Infection of bone
• Infective blepharitis
• Keratoconjunctivitis
• Klebsiella Pneumoniae Osteomyelitis
• + 29 more

Off-label uses (4)

• Exposure keratoconjunctivitis
• Neuropathic corneal ulcer
• Pyrexia of unknown origin
• Superficial Ocular Infection

Contraindications (28)

• Bacterial infection of eye
• Dehydration
• Diabetes mellitus
• Disorder of the 8th Cranial Nerve
• Eye infection
• Fungal infection of eye
• Glaucoma
• Herpes simplex dendritic keratitis
• Herpes simplex keratitis
• Herpes zoster ophthalmicus
• Hypocalcemia
• Hypomagnesemia
• Infant Botulism
• Kidney disease
• Krukenberg spindle
• Myasthenia gravis
• Ocular hypertension
• Open-angle glaucoma
• Parkinsonism
• Pregnancy, function
• Pseudomembranous enterocolitis
• Severe myopia
• Tinnitus
• Tobramycin Toxicity
• Tuberculosis of eye
• Vaccinia keratitis
• Vertigo
• Viral eye infection

Mechanism & targets

• Established pharmacologic class: Aminoglycoside Antibacterial

Molecular targets (3)

Target	Gene	Action	Activity
Heparanase	HPSE	unknown	IC50 6.05
Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)	mphB	unknown	Km 5.82
Taste receptor type 2 member 20	TAS2R20	agonist	EC50 4.29

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2011-07-20	EMA	—	MYLAN IRELAND LIMITED	Yes
1975-06-11	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
J01GB01	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › AMINOGLYCOSIDE ANTIBACTERIALS › Other aminoglycosides
S01AA12	SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIINFECTIVES › Antibiotics

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• FDA label: MT-RNR1 · Actionable PGx
• HCSC label: MT-RNR1 · Actionable PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Infective pulmonary exacerbation of cystic fibrosis	4079.9
Hospitalisation	1132.2
Cystic fibrosis	792.1
Pulmonary function test decreased	535.8
Pseudomonas infection	518.6
Haemoptysis	367.1
Pneumonia	354.0
Cough	340.7
Acute kidney injury	278.4
Ototoxicity	264.8
Ill-defined disorder	219.8
Off label use	205.4

Chemical structure

• Molecular formula: C₁₈H₃₇N₅O₉
• Molecular weight: 467.52 g/mol
• CAS number: 32986-56-4
• InChIKey: NLVFBUXFDBBNBW-PBSUHMDJSA-N
• PubChem CID: 36294

NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Tobramycin used for?

DrugCentral lists the following indications for Tobramycin: Allergic conjunctivitis, Anterior uveitis, Bacterial conjunctivitis, Bacterial infection due to Klebsiella pneumoniae, Bacterial infection due to Serratia, Bacterial meningitis, Bacterial peritonitis and Bacterial septicemia and others.

How does Tobramycin work?

Its molecular targets in DrugCentral include HPSE, mphB and TAS2R20 (agonist).

When was Tobramycin first approved?

Tobramycin was first approved by the FDA in 1975.

What drug class does Tobramycin belong to?

Tobramycin is in the Aminoglycoside Antibacterial class.

What is the chemical formula of Tobramycin?

Tobramycin has the molecular formula C18H37N5O9 and a molecular weight of 467.52 g/mol.

Sources

• DrugCentral drug card 2684 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1747 — compound record and bioactivity
• PubChem CID 36294 — chemical identifiers
• DrugBank DB00684 — drug record
• FDA UNII VZ8RRZ51VK — substance identity
• DailyMed: FDA labels for Tobramycin — current prescribing information (label search)
• UniProt Q9Y251 (HPSE) — target protein
• UniProt P59543 (TAS2R20) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.